The mission of the Medication Addiction Treatment Initiative in the VA (MAT-VA) is to improve health outcomes in Veterans with Substance Use Disorders (SUDs) through the use of medications—in combination with non-pharmacological treatment approaches—in a wide variety of outpatient and inpatient clinical environments. To accomplish this mission, MAT-VA provides:
- Education
- Peer to peer mentoring
- External facilitation of evidence-based care
- Monitoring and provision of guidance's and regulations
- Implementation of innovative approaches of clinical care
Sponsor: US Department of Veterans Affairs. If from Veteran's Affairs, you can access the MAT-VA SharePoint at tinyurl.com/MATVA-VHA
The MAT-VA’s journal club generally occurs on the 3rd and 4th Wednesday of each month. To receive an invite to one of these calls, be added to the listserv, or for questions, please email Spencer.Calder@va.gov.
Upcoming Presentation: "Buprenorphine 101 for the Non-Addictionologist." Presented by Adam Gordon on January 22nd at 12-1pm ET.
You can find a complete list of the MAT-VA's Journal Club webinars below:
| Month | Webinar Topic | Presenter(s) |
|
June 20, 2018 |
How to do Addiction Care in Primary Care
|
Adam Gordon |
|
July 18, 2018 |
XR Buprenorphine: The Science | Adam Gordon |
| July 25, 2018 | Journal Club: Primary Care and The Opioid-Overdose Crisis - Buprenorphine Myths and Realities | Adam Gordon |
| August 1, 2018 |
DISCUSSION: Difficult Cases and Q&A |
Adam Gordon |
| September 5, 2018 |
Journal Club: Buprenorphine Myths and Realities |
Adam Gordon |
|
September 12, 2018 |
DISCUSSION: Resources and Q&A |
Adam Gordon |
| September 19, 2018 |
Buprenorphine Home Induction: The Latest |
Adam Gordon |
| September 26, 2018 |
Journal Club: Evaluation of ORC |
Katherine Hoggatt |
| October 17, 2018 |
Stepped Care for OUD - What is it and how can I do it? |
Adam Gordon |
| October 24, 2018 |
Journal Club: Epidemiology of SUD among Veterans |
Katherine Hoggatt |
| November 21, 2018 |
Language of Addiction: Does This Reinforce Stigma? |
Adam Gordon |
| Month | Webinar Topic | Presenter(s) |
|
February 27, 2019 |
Buprenorphine for pain |
Adam Gordon |
|
March 13, 2019 |
Buprenorphine for pain | Adam Gordon |
| March 27, 2019 | Journal Club: Pain and Addiction: An Integrative Therapeutic Approach | Ajay Manhapra |
| April 17, 2019 |
Perception of Patients of Medication Addiction Treatment - a Primary Care Focus |
Adam Gordon |
| April 25, 2019 |
Association Between Opioid Dose Variability and Opioid Overdose Among Adults Prescribed Long-term Opioid Therapy |
Stephan Kertesz |
|
May 8, 2019 |
The Addiction Mini-Residency Program |
Ellen Edens, Gabriela Garcia |
| June 19, 2019 |
Patient Navigation for Pregnant Women with Opioid Use Disorder |
Jerry Cochran and Team |
| August 28, 2019 |
Telemedicine-delivered treatment interventions for substance use disorders |
Lin, Lewei (Allison) |
| October 16, 2019 |
Medications for OUD in VA: Historical Trends, Contemporary Strategies. |
Jessica J, Wyse |
| November 20, 2019 |
VHA Notice 2019-18: Buprenorphine Prescribing for Opioid Use Disorder |
Adam Gordon |
|
|
| Month | Webinar Topic | Presenter(s) |
| January 2020 | Predictors of availability of long-acting medication for opioid use disorder | Dr. Chelsea Leigh Shover |
|
February 2020 |
"Everything is not right anymore": Buprenorphine experiences in an era of illicit fentanyl | Dr. Shannon Miller and Sydney Silverstein, PhD |
| May 20, 2020 |
The conundrum of long term opioids for pain: "Darned if you do, darned if you don’t” |
Dr. Ajay Manhapra |
| May 27, 2020 |
Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of MAT for veterans with OUD in low-performing facilities |
Hildi Hagedorn, PhD |
| June 24, 2020 |
‘Rapid Transition From Methadone to Buprenorphine Utilizing a Micro-dosing Protocol in the Outpatient Veteran Affairs Setting’ |
Dr. Joao P De Aquino Lima |
| July 15, 2020 |
Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems |
Dr. A J Saxon |
| July 22, 2020 |
Racial/Ethnic Differences in the Medical Treatment of Opioid Use Disorders Within the VA Healthcare System Following Non-Fatal Opioid Overdose |
Dr. Utibe Essien |
| August 19, 2020 |
“Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs” |
Dr. Andrea K. Finlay |
| August 26, 2020 |
Impact of opioid dose escalation on the development of substance use disorders, accidents, self-inflicted injuries, opioid overdoses and alcohol and non-opioid drug-related overdoses: a retrospective cohort study |
Dr. Corey Hayes |
| Sept. 23, 2020 |
‘A computerized anxiety sensitivity intervention for opioid use disorders: A pilot investigation among veterans’ |
Amanda M. Raines PhD |
| October 21, 2020 |
Treating Alcohol Use Disorder in the U.S. Veterans: The Role of Traumatic Brain Injury |
Dr. Ricardo Jorge |
| October 28, 2020 |
Developing a clinical decision support for opioid use disorders: a NIDA center for the clinical trials network working group report. |
Dr. G Bart and Dr. Andrew Saxon |
| Month | Webinar Topic | Presenter(s) |
|
January 20, 2021
|
"Promoting Patient-Centeredness in Opioid Deprescribing: a Blueprint for De-implementation Science" | Stefan G. Kertesz, MD, MSc; Allyson L. Varley, PhD |
|
January 27, 2021 |
Drug Overdose and Suicide Among Veteran Enrollees in the VHA: Comparison Among Local, Regional, and National Data | Stephen A. Mudra, MD |
| February 17, 2021 |
Nonconsensual Dose Reduction Mandates are Not Justified Clinically or Ethically: An Analysis |
Dr. Ajay Manhapra |
| February 24, 2021 |
The Opioid Epidemic In Veterans Who Were Homeless Or Unstably Housed |
Amanda Midboe |
| March 17, 2021 |
Depression and Buprenorphine Treatment in Patients with Non-cancer Pain and Prescription Opioid Dependence without Comorbid Substance Use Disorders |
Dr. Jeffrey F Scherrer |
| March 24, 2021 |
Race, Ethnicity, and Clinical Features of Alcohol Use Disorder Among US Military Veterans: Results From the National Health and Resilience in Veterans Study |
Dr. Megan Carr & Dr. Kristin Serowik |
| May 19, 2021 |
An Integrated Pain Team Model: Impact on Pain-Related Outcomes and Opioid Misuse in Patients with Chronic Pain |
Dr. Carolyn Gibson & Dr. Francesca Nicosia |
| May 26, 2021 |
Impact of Continuing Care on Recovery From Substance Use Disorder |
Dr. James McKay |
| June 16, 2021 |
Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder |
Beth M. DeRonne, PharmD |
| June 23, 2021 |
Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder |
Allison M. Gustavson, PT, DPT, PhD |
| July 21, 2021 |
Assessment of the impact of an opioid-specific education series on rates of medication-assisted treatment for opioid use disorder in veterans |
Taylor R. Kirby |
| August 18, 2021 |
Evaluation of a Fentanyl Test Kit Pilot Program at the San Francisco VA Health Care System |
Tessa Rife-Pennington, PharmD, BCGP |
| August 25, 2021 | Opioid Use Disorder and Hospitalizations: Recognition and treatment, challenges and opportunities | Dr. Michael Spiker |
| September 22, 2021 | Burden of cannabis use and disorder in the U.S. veteran population: Psychiatric comorbidity, suicidality, and service utilization | Melanie Hill Sonya Norman |
| October 20, 2021 | Management of Kratom Dependence with Buprenorphine and Naloxone in a Veteran Population | Jamie Lei, PharmD, BCPP |
| November 17, 2021 | Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: Observational study | Dr. Elizabeth Oliva |
| Month | Webinar Topic | Presenter(s) |
| January 19, 2022 | Roles and perceptions of nurses during implementation of a medication treatment for opioid use disorder national initiative | Ashley Radmall |
|
January 26, 2022 |
Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial | Andrew Saxon, Yih-Ing Hser |
| February 16, 2022 |
Starting buprenorphine in the fentanyl era: challenges and approaches |
Ashish Thakrar |
| March 16, 2022 |
Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans |
Sandra Springer, Ismene Petrakis |
| March 23, 2022 |
Examining changing patterns of Veteran overdose |
Lewei (Allison) Lin MD, MS |
| April 27, 2022 |
Beyond State Scope of Practice Laws for Advanced Practitioners: Additional Supervision Requirements for Buprenorphine Prescribing |
Basia Andraka-Cristou |
| June 15, 2022 |
Intranasal Oxytocin for Stimulant Use Disorder Among Male Veterans Enrolled in an Opioid Treatment Program: A Randomized Controlled Trial |
Alex Hickok |
| June 22, 2022 |
Buprenorphine 101 for the non-Addictionologist |
Adam Gordon |
| July 27, 2022 |
Effectiveness of a substance use treatment program for veterans with chronic pain and opioid use disorder |
Ralph Ward |
| September 21, 2022 | Rapid Overlap Initiation Protocol Using Low Dose Buprenorphine for Opioid Use Disorder Treatment in an Outpatient Setting: A Case Series | Leslie Suen |
| September 28, 2022 |
Development of an intravenous low-dose buprenorphine initiation protocol |
Lindsay A. Jablonski
Alia Bodnar Rosalyn Stewart |
| October 19, 2022 |
Buprenorphine 101 for the non-Addictionologist |
Adam Gordon |
| October 26, 2022 | Daniel Gottlieb Bradley Watts |
|
| November 16, 2022 | Association between opioid therapy trajectories and potential opioid-related adverse health events | Corey Hayes |
| Month | Webinar Topic | Presenter(s) |
| January 18, 2023 | Use of retention on buprenorphine for opioid use disorder in the VA following COVID-19-related telehealth policy changes | Madeline Frost |
|
February 15, 2023 |
Buprenorphine 101 for the non-Addictionologist
|
Adam Gordon |
| March 15, 2023 | Buprenorphine 101 for the non-Addictionologist | Adam Gordon |
| April 19, 2023 |
Buprenorphine 101 for the non-Addictionologist |
Adam Gordon |
| April 26, 2023 |
Posttraumatic stress disorder, suicide, and unintended overdose death in later life: A national cohort study of veterans aged 50 and older |
Randall Kuffel, Amy Byers, Thomas Neylan |
| May 17, 2023 |
Buprenorphine 101 for the non-Addictionologist |
Adam Gordon |
| June 21, 2023 |
Craving of prescription opioids among veterans with chronic pain |
Irina Strigo, Tiffany Toor |
| June 28, 2023 |
Causes of alcohol-attributable death and associated years of potential life lost among LGB and non-LGB veteran men and women in Veterans Health Administration |
Nicholas Livingston |
| July 19, 2023 | Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis. | Fernando Montero |
| August 23, 2023 | Unhealthy alcohol use and brief intervention rates among High and low complexity Veterans seeking primary care services in the VHA | Mielin Jia-Richards |
| September 27, 2023 | Ask and Ask Again: Repeated Screening for Smoking Increases Likelihood of Prescription for Cessation Treatment Among Women Veterans |
Claire Than, Bevanne Bean-Mayberry, Catherine Schweizer, Melissa Farmer Coste |
| October 26, 2023 | Buprenorphine 101 for the Non-Addictionologist Training | Adam Gordon |
| Month | Webinar Topic | Presenter(s) |
| January 17, 2024 | Increasing Risk of Cannabis Use Disorder Among U.S. Veterans with Chronic Pain: 2005-2019 | Zachary Mannes, PhD, MPH |
| January 24, 2024 | Buprenorphine 101 for the non-Addictionologist | Adam Gordon, MD, MPH |
| February 21, 2024 | Technology-Assisted Buprenorphine Treatment in Rural and Nonrural Settings: Two Randomized Clinical Trials | Kelly Peck, PhD |
| March 20, 2024 | Impact of 8 lifestyle factors on mortality and life expectancy among United States veterans: The Million Veteran Program | Xuan-Mai Nguyen, MD, PhD; Yanping Li, MD, PhD; Peter Wilson, MD |
| March 27, 2024 | Diagnostic profiles associated with long-term opioid therapy in active duty servicemembers | Steven Dufour, PhD; Joshua Gray, PhD |
| April 24, 2024 | Buprenorphine 101 for the non-Addictionologist | Adam Gordon, MD, MPH |
| May 15, 2024 | Implementing alcohol-related care in VA hepatology clinics | Madeline Frost, PhD |
| June 19, 2024 | Opioid prescription and risk of atrial fibrillation in younger Veterans | Parul Gandhi, Arshjot Khokhar, Lori Bastian, Brian Malm |
| September 18, 2024 | Withdrawal During Outpatient Low Dose Buprenorphine Initiation in People Who Use Fentanyl: A Retrospective Cohort Study | Benjamin Jones, MD |
| September 24, 2024 | Associations Between a Primary Care-Delivered Alcohol-Related Brief Intervention and Subsequent Opioid-Related Outcomes | Daniel Blalock, PhD; Janet Grubber, MSPH |
| October 16, 2024 | Opioid Use Disorder Management and Prescription Opioid Harms in the Context of Aging | Minhee Sung, MD |
| October 23, 2024 | Buprenorphine 101 for the Non-Addictionologist | Adam Gordon, MD, MPH |
| November 20, 2024 | Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives | Alicia Bergman, PhD; Rebecca Oberman, MSW, MPH; Evelyn Chang, MD, MSHS |